Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05741437
Other study ID # A129_01BE2225
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date April 11, 2023
Est. completion date September 5, 2023

Study information

Verified date March 2024
Source Chong Kun Dang Pharmaceutical
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A clinical trial to compare and evaluate the safety and pharmacokinetics of CKD-378


Description:

A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety after Oral Administration of CKD-378 and Co-administration of D745, D150 in Healthy Adults


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date September 5, 2023
Est. primary completion date August 31, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 55 Years
Eligibility Inclusion Criteria: 1. Healthy adult aged between 19 to 55 at screening 2. Weight = 50kg(man) or 50kg(woman) 3. Body mass index (BMI) of 18.5 to 27.0kg/m2 4. If female, one of following conditions. Menopause (no menstruation more than 2 years) or surgically sterilized. 5. Those who agree to contraception from the first IP dosing day till 28 days after the last dosing day and decide not to provide sperm during the participation of clinical trial 6. Those who voluntarily decide to participate in paper and agree to comply with the cautions after fully understand the detailed description of this clinical trial Exclusion Criteria: 1. Those who have clinically significant disease or medical history of Hepatopathy, Renal dysfunction, Neurological disorder, Immunity disorder, Respiratory disorder, Genitourinary system disorder, Haemato-oncology disorder, Cardiovascular disorder or Psychical disorder. 2. Those who are vulnerable to dehydration due to lack of ability in oral intake or have dehydration. 3. Those who had medical examination requiring radioactive iodine contrast material injected through IV 48 hours prior to first IP administration. 4. Those who have significant disease or medical history of urinary infection. 5. Those who have genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption 6. Those who have a history of gastrointestinal surgery except simple appendectomy and hernia surgery which can interfere with drug absorption. 7. Those who have hypersensitivity to the main constituents or components of the investigational drug such as empagliflozin, metformin. 8. Those who have tested inappropriate in screening test 28 days prior to IP administration. - AST, ALT > 1.5 times higher than upper normal level - eGFR (estimated Glomerular Filtration Rate, which is calculated by MDRD) < 60 mL/min/1.73m2 - "Positive" or "Reactive" test result of Hepatitis B & C, HIV, RPR - Under 5 min resting condition, systolic blood pressure >150 mmHg or or <90 mmHg, diastolic blood pressure >100 mmHg or <50 mmHg. 9. Those who has a drug abuse history within one year or positive reaction on urine drug screening test. 10. Woman who are pregnant or breastfeeding 11. Those who exceed an alcohol, caffeine and cigarette consumption (caffeine> 5 cups/day, alcohol> 210g/week, smoking> 10 cigarettes/day) and not able to stop on smoking, caffeine and alcohol 12. Those who have used following drugs that can interfere with the study or have impact on safety of the subject. - ETC, herbal medicinal preparations within 14 days before the first dosing date - OTC, vitamins, health supplement within 7 days before the first dosing date - Depot injection or implantation within 30 days before the first dosing date 13. Those who received investigational products or participated in bioequivalence test within 180 days before the first administration of clinical trial drugs 14. Those who donated whole blood within 60 days before the first date of administration and donated ingredients within 30 days 15. Those who have received blood transfusion in 30 days 16. Those who are deemed insufficient to participate in clinical study by investigators

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CKD-378, QD, PO Drug: D745, D150, QD, PO
Durg: CKD-378, QD, PO Drug: D745, D150, QD, PO

Locations

Country Name City State
Korea, Republic of Severance Hospital Seoul Seodaemun-gu

Sponsors (1)

Lead Sponsor Collaborator
Chong Kun Dang Pharmaceutical

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary 1. AUCt of CKD-378: Area under the concentration-time curve time zero to time Pre-dose(0 hour) to 48 hours
Primary 2. Cmax of CKD-378: Maximum plasma concentration of the drug Pre-dose(0 hour) to 48 hours
See also
  Status Clinical Trial Phase
Completed NCT02127762 - The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy N/A
Withdrawn NCT04569214 - The Efficacy and Safety of PAZ320 on PPG and Insulin Blood Levels in Type II Diabetic Patients Phase 2
Completed NCT01698528 - Evaluation of a Prototype Diabetes Management System Applied to Insulin Initiation and Titration N/A
Completed NCT00985114 - Safety and Efficacy Study of EndoBarrier in Subjects With Type II Diabetes and Obesity N/A
Active, not recruiting NCT05120219 - A Study to Assess the Effect of Food on HR20033 and Pharmacokinetic After Multiple Dose in Healthy Volunteers Phase 1
Completed NCT04893135 - Impact of the Rapid Normalization of Chronic Hyperglycemia and the Practice of Moderate Physical Activity on the "Receptor Activator of Nuclear Factor-kappa B Ligand / Osteoprotégérine (RANKL / OPG) System in Patients Living With Type II Diabetes N/A
Not yet recruiting NCT05108350 - A Study to Assess the Bioequivalence of Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Healthy Chinese Subjects Phase 1
Completed NCT02586129 - Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes Phase 3
Completed NCT02914743 - Providing Preventive Periodontal Treatment to Hospitalized Patients With Diabetes N/A
Completed NCT04540016 - Mass Balance and Biotransformation of [14C]HSK7653 in Human Phase 1
Completed NCT02429258 - Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin Phase 4
Completed NCT01055223 - Fracture Risk With Thiazolidinediones N/A
Terminated NCT02365233 - Fatty Liver Study in Patients With Type II Diabetes Phase 4
Completed NCT05878587 - Burger Allen Exercises in Knee OA With Type II Diabetes N/A
Completed NCT04768673 - A Study to Investigate the PK and Safety of CKD-393 Phase 1
Not yet recruiting NCT05028140 - Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus Phase 3
Terminated NCT01804777 - Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes Early Phase 1
Completed NCT01619332 - Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763 Phase 1/Phase 2
Active, not recruiting NCT06387433 - Effectiveness of an mHealth Mobile App N/A
Not yet recruiting NCT01591525 - Diabetes Mellitus Community Based Screening in Minority Populations N/A